Nyanda Elias Ntinginya

Author

National Institute for Medical Research ORCID

Also Known As

David Aanensen, E Nyanda, Elias Ntinginya Nyanda, Elias Nyanda, Elias Nyanda Ntinginya, Ian Sanne, Mtafya Bariki, N Ntinginya, N. E. Ntinginya, N. Elias Ntinginya

185

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

National Institute for Medical Research Ludwig-Maximilians-Universität München German Center for Infection Research Kilimanjaro Christian Medical Centre University of St Andrews

About

Nyanda Elias Ntinginya is an author at National Institute for Medical Research specializing in medicine, tuberculosis, and tuberculosis prevention.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1K
2	Public Health	3	3	64
3	Engineering	1	1	17
4	Allergy	1	1	136
5	Environmental Health	1	1	17

Nyanda Elias Ntinginya

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages David Stucki, Daniela Brites, Leïla Jeljeli, Nature Genetics Pulmonary TuberculosisTuberculosis PreventionTuberculosisMicrobiologyMedicine	2016	465
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial Martin J. Boeree, Norbert Heinrich, Rob E. Aarnoutse, The Lancet Infectious Diseases	2016	379
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt, The Lancet Pulmonary TuberculosisPhase 2BTuberculosis PreventionPharmacologyTuberculosis	2015	248
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial Conor Tweed, Rodney Dawson, Divan A. Burger, The Lancet Respiratory Medicine	2019	143
Assessment of the novel T-cell activation marker–tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study Damien Portevin, Félicien Moukambi, Petra Clowes, The Lancet Infectious Diseases Pulmonary TuberculosisAllergyImmunodeficienciesTuberculosis PreventionImmunology	2014	136
Dispensing Antibiotics without Prescription at Community Pharmacies and Accredited Drug Dispensing Outlets in Tanzania: A Cross-Sectional Study Pendo Ndaki, Martha F. Mushi, Joseph R. Mwanga, Antibiotics	2021	86
The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations Ruth Bowness, Martin J. Boeree, Rob E. Aarnoutse, Journal of Antimicrobial Chemotherapy	2014	73
Xpert MTB/RIF Ultra assay for the diagnosis of pulmonary tuberculosis in children: a multicentre comparative accuracy study Issa Sabi, Andrea Rachow, Daniel Mapamba, Journal of Infection Pulmonary TuberculosisMedicinePediatricsDiagnosisPediatric Lung Disease	2018	70
Tanzania's position on the COVID-19 pandemic Sayoki Mfinanga, Nicholaus P. Mnyambwa, Daniel T. R. Minja, The Lancet	2021	70
TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB – a study protocol Andrea Rachow, Olena Ivanova, Robert S. Wallis, BMC Pulmonary Medicine	2019	69

Page 1